316 related articles for article (PubMed ID: 17431029)
1. Metabolism, pharmacokinetics, and excretion of a nonpeptidic substance P receptor antagonist, ezlopitant, in normal healthy male volunteers: characterization of polar metabolites by chemical derivatization with dansyl chloride.
Prakash C; O'Donnell J; Khojasteh-Bakht SC
Drug Metab Dispos; 2007 Jul; 35(7):1071-80. PubMed ID: 17431029
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of ezlopitant, a novel non-peptidic neurokinin-1 receptor antagonist in preclinical species and metabolite kinetics of the pharmacologically active metabolites.
Reed-Hagen AE; Tsuchiya M; Shimada K; Wentland JA; Obach RS
Biopharm Drug Dispos; 1999 Dec; 20(9):429-39. PubMed ID: 10951432
[TBL] [Abstract][Full Text] [Related]
3. Disposition and metabolism of radiolabeled casopitant in humans.
Pellegatti M; Bordini E; Fizzotti P; Roberts A; Johnson BM
Drug Metab Dispos; 2009 Aug; 37(8):1635-45. PubMed ID: 19420128
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin (PF-04971729) in healthy male subjects.
Miao Z; Nucci G; Amin N; Sharma R; Mascitti V; Tugnait M; Vaz AD; Callegari E; Kalgutkar AS
Drug Metab Dispos; 2013 Feb; 41(2):445-56. PubMed ID: 23169609
[TBL] [Abstract][Full Text] [Related]
5. Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers.
Takusagawa S; van Lier JJ; Suzuki K; Nagata M; Meijer J; Krauwinkel W; Schaddelee M; Sekiguchi M; Miyashita A; Iwatsubo T; van Gelderen M; Usui T
Drug Metab Dispos; 2012 Apr; 40(4):815-24. PubMed ID: 22269146
[TBL] [Abstract][Full Text] [Related]
6. Narrow-bore high-performance liquid chromatography in combination with ionspray tandem mass spectrometry for the determination of the substance P receptor antagonist ezlopitant and its two active metabolites in plasma.
Kamel A; Prakash C; Saverino C; Obach B; Fouda H
J Chromatogr B Biomed Sci Appl; 2000 Oct; 748(1):179-88. PubMed ID: 11092597
[TBL] [Abstract][Full Text] [Related]
7. Metabolism, pharmacokinetics, and excretion of the substance P receptor antagonist CP-122,721 in humans: structural characterization of the novel major circulating metabolite 5-trifluoromethoxy salicylic acid by high-performance liquid chromatography-tandem mass spectrometry and NMR spectroscopy.
Colizza K; Awad M; Kamel A
Drug Metab Dispos; 2007 Jun; 35(6):884-97. PubMed ID: 17360832
[TBL] [Abstract][Full Text] [Related]
8. Characterization of metabolites of a NK1 receptor antagonist, CJ-11,972, in human liver microsomes and recombinant human CYP isoforms by liquid chromatography/tandem mass spectrometry.
Prakash C; Lin J; Colizza K; Miao Z
Rapid Commun Mass Spectrom; 2007; 21(17):2822-32. PubMed ID: 17661339
[TBL] [Abstract][Full Text] [Related]
9. Metabolism, excretion, and pharmacokinetics of (3-{[4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid, an EP2 receptor-selective prostaglandin E2 agonist, in male and female Sprague-Dawley rats.
Johnson KA; Prakash C
Drug Metab Dispos; 2005 Aug; 33(8):1191-201. PubMed ID: 15886349
[TBL] [Abstract][Full Text] [Related]
10. Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans.
Prakash C; Kamel A; Gummerus J; Wilner K
Drug Metab Dispos; 1997 Jul; 25(7):863-72. PubMed ID: 9224781
[TBL] [Abstract][Full Text] [Related]
11. Metabolism of ezlopitant, a nonpeptidic substance P receptor antagonist, in liver microsomes: enzyme kinetics, cytochrome P450 isoform identity, and in vitro-in vivo correlation.
Obach RS
Drug Metab Dispos; 2000 Sep; 28(9):1069-76. PubMed ID: 10950851
[TBL] [Abstract][Full Text] [Related]
12. Anti-emetic activity of the novel nonpeptide tachykinin NK1 receptor antagonist ezlopitant (CJ-11,974) against acute and delayed cisplatin-induced emesis in the ferret.
Tsuchiya M; Fujiwara Y; Kanai Y; Mizutani M; Shimada K; Suga O; Ueda S; Watson JW; Nagahisa A
Pharmacology; 2002 Nov; 66(3):144-52. PubMed ID: 12372904
[TBL] [Abstract][Full Text] [Related]
13. The metabolic disposition of aprepitant, a substance P receptor antagonist, in rats and dogs.
Huskey SE; Dean BJ; Doss GA; Wang Z; Hop CE; Anari R; Finke PE; Robichaud AJ; Zhang M; Wang B; Strauss JR; Cunningham PK; Feeney WP; Franklin RB; Baillie TA; Chiu SH
Drug Metab Dispos; 2004 Feb; 32(2):246-58. PubMed ID: 14744948
[TBL] [Abstract][Full Text] [Related]
14. Metabolism and Disposition of a Novel B-Cell Lymphoma-2 Inhibitor Venetoclax in Humans and Characterization of Its Unusual Metabolites.
Liu H; Michmerhuizen MJ; Lao Y; Wan K; Salem AH; Sawicki J; Serby M; Vaidyanathan S; Wong SL; Agarwal S; Dunbar M; Sydor J; de Morais SM; Lee AJ
Drug Metab Dispos; 2017 Mar; 45(3):294-305. PubMed ID: 27993930
[TBL] [Abstract][Full Text] [Related]
15. Metabolism and disposition of a selective alpha(7) nicotinic acetylcholine receptor agonist in humans.
Shaffer CL; Gunduz M; Scialis RJ; Fang AF
Drug Metab Dispos; 2007 Jul; 35(7):1188-95. PubMed ID: 17446264
[TBL] [Abstract][Full Text] [Related]
16. Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers.
Ling J; Johnson KA; Miao Z; Rakhit A; Pantze MP; Hamilton M; Lum BL; Prakash C
Drug Metab Dispos; 2006 Mar; 34(3):420-6. PubMed ID: 16381666
[TBL] [Abstract][Full Text] [Related]
17. Absorption, metabolism, and excretion of [(14)C]MK-0524, a prostaglandin D(2) receptor antagonist, in humans.
Karanam B; Madeira M; Bradley S; Wenning L; Desai R; Soli E; Schenk D; Jones A; Dean B; Doss G; Garrett G; Crumley T; Nirula A; Lai E
Drug Metab Dispos; 2007 Jul; 35(7):1196-202. PubMed ID: 17431030
[TBL] [Abstract][Full Text] [Related]
18. Metabolism and excretion of a new anxiolytic drug candidate, CP-93, 393, in healthy male volunteers.
Prakash C; Cui D; Baxter JG; Bright GM; Miceli J; Wilner K
Drug Metab Dispos; 1998 May; 26(5):448-56. PubMed ID: 9571226
[TBL] [Abstract][Full Text] [Related]
19. Absorption, metabolism, and excretion of [14C]imidafenacin, a new compound for treatment of overactive bladder, after oral administration to healthy male subjects.
Ohmori S; Miura M; Toriumi C; Satoh Y; Ooie T
Drug Metab Dispos; 2007 Sep; 35(9):1624-33. PubMed ID: 17567733
[TBL] [Abstract][Full Text] [Related]
20. Mass Balance and Metabolic Pathways of Eliapixant, a P2X3 Receptor Antagonist, in Healthy Male Volunteers.
Reif S; Schultze-Mosgau MH; Engelen A; Piel I; Denner K; Roffel A; Tiessen R; Klein S; Francke K; Rottmann A
Eur J Drug Metab Pharmacokinet; 2024 Jan; 49(1):71-85. PubMed ID: 38044419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
